Pharmaceutical stocks include large-cap drug makers and specialty pharma companies. AI analysis focuses on pipeline value, patent expiration risks, pricing power, and international revenue diversification from SEC filings.
Top Pharmaceutical Stocks in 2026
Top-rated pharmaceutical stocks ranked by AI confidence score. Dual AI analysis (Claude + ChatGPT) based on SEC 10-K and 10-Q filings. Last Updated: June 2026
LLY
Confidence
86%
ELTP
Confidence
84%
CRMD
Confidence
82%
UTHR
Confidence
82%
VRTX
Confidence
81%
REGN
Confidence
80%
AUPH
Confidence
78%
CPRX
Confidence
78%
ZTS
Confidence
78%
HRMY
Confidence
76%
BMRN
Confidence
76%
COLL
Confidence
75%
All Pharmaceutical Stocks (491)
| Ticker | Company | AI Rating | Confidence | Action |
|---|---|---|---|---|
| ADTX | Aditxt, Inc. | D | 98% | View Analysis → |
| SKVI | SKINVISIBLE, INC. | D | 98% | View Analysis → |
| PRPH | ProPhase Labs, Inc. | D | 97% | View Analysis → |
| KAYS | Kaya Holdings, Inc. | D | 96% | View Analysis → |
| RGPX | REGENEREX PHARMA, INC. | D | 96% | View Analysis → |
| GCAN | Greater Cannabis Company, Inc. | D | 96% | View Analysis → |
| EMMA | Emmaus Life Sciences, Inc. | D | 96% | View Analysis → |
| PETS | PETMED EXPRESS INC | D | 95% | View Analysis → |
| TRAW | Traws Pharma, Inc. | D | 95% | View Analysis → |
| TCRT | Alaunos Therapeutics, Inc. | D | 95% | View Analysis → |
| SHPH | Shuttle Pharmaceuticals Holdings, Inc. | D | 95% | View Analysis → |
| PCSA | Processa Pharmaceuticals, Inc. | D | 95% | View Analysis → |
| PTN | PALATIN TECHNOLOGIES INC | D | 95% | View Analysis → |
| TPST | Tempest Therapeutics, Inc. | D | 95% | View Analysis → |
| ZVSA | ZyVersa Therapeutics, Inc. | D | 95% | View Analysis → |
| VICP | Vicapsys Life Sciences, Inc. | D | 95% | View Analysis → |
| VCNX | VACCINEX, INC. | D | 95% | View Analysis → |
| STEK | Stemtech Corp | D | 95% | View Analysis → |
| SMNRW | Semnur Pharmaceuticals, Inc. | D | 95% | View Analysis → |
| SLNCF | Silence Therapeutics plc | D | 95% | View Analysis → |
| RTEZ | REST EZ Inc. | D | 95% | View Analysis → |
| OTLC | Oncotelic Therapeutics, Inc. | D | 95% | View Analysis → |
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | D | 95% | View Analysis → |
| PKTX | ProtoKinetix, Inc. | D | 95% | View Analysis → |
| NIKA | NIKA PHARMACEUTICALS, INC | D | 95% | View Analysis → |
| MDCXW | Medicus Pharma Ltd. | D | 95% | View Analysis → |
| MCUJF | MEDICURE INC | D | 95% | View Analysis → |
| GALT | GALECTIN THERAPEUTICS INC | D | 94% | View Analysis → |
| ABVC | ABVC BIOPHARMA, INC. | D | 94% | View Analysis → |
| BTAI | BioXcel Therapeutics, Inc. | D | 94% | View Analysis → |
| CLNN | Clene Inc. | D | 94% | View Analysis → |
| INO | INOVIO PHARMACEUTICALS, INC. | D | 94% | View Analysis → |
| BYSI | BeyondSpring Inc. | D | 94% | View Analysis → |
| NASC | Can B Corp | D | 94% | View Analysis → |
| ITRM | Iterum Therapeutics plc | D | 94% | View Analysis → |
| GELS | Gelteq Ltd | C | 94% | View Analysis → |
| ERNAW | Ernexa Therapeutics Inc. | D | 94% | View Analysis → |
| ENSCW | Ensysce Biosciences, Inc. | D | 94% | View Analysis → |
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | D | 93% | View Analysis → |
| ELTX | Elicio Therapeutics, Inc. | D | 93% | View Analysis → |
| IOBT | IO Biotech, Inc. | D | 93% | View Analysis → |
| INTI | Inhibitor Therapeutics, Inc. | D | 93% | View Analysis → |
| EVFM | Evofem Biosciences, Inc. | D | 93% | View Analysis → |
| PPCB | Propanc Biopharma, Inc. | D | 92% | View Analysis → |
| JAGX | Jaguar Health, Inc. | D | 92% | View Analysis → |
| CNSP | CNS Pharmaceuticals, Inc. | D | 92% | View Analysis → |
| SKYE | Skye Bioscience, Inc. | D | 92% | View Analysis → |
| SPRY | ARS Pharmaceuticals, Inc. | D | 92% | View Analysis → |
| CPHI | CHINA PHARMA HOLDINGS, INC. | D | 92% | View Analysis → |
| CRVO | CervoMed Inc. | D | 92% | View Analysis → |
| IBO | IMPACT BIOMEDICAL INC. | D | 92% | View Analysis → |
| ARTL | ARTELO BIOSCIENCES, INC. | C | 92% | View Analysis → |
| SILO | Silo Pharma, Inc. | D | 92% | View Analysis → |
| SVRA | Savara Inc | D | 92% | View Analysis → |
| MAIA | MAIA Biotechnology, Inc. | D | 92% | View Analysis → |
| XCUR | EXICURE, INC. | D | 92% | View Analysis → |
| PMHS | Polomar Health Services, Inc. | D | 92% | View Analysis → |
| ORGS | Orgenesis Inc. | D | 92% | View Analysis → |
| NWBO | NORTHWEST BIOTHERAPEUTICS INC | D | 92% | View Analysis → |
| MANE | Veradermics, Inc | D | 92% | View Analysis → |
| INDP | Indaptus Therapeutics, Inc. | D | 91% | View Analysis → |
| MBRX | Moleculin Biotech, Inc. | D | 91% | View Analysis → |
| NBY | NovaBay Pharmaceuticals, Inc. | D | 91% | View Analysis → |
| HLYK | HealthLynked Corp | D | 91% | View Analysis → |
| EVMN | Evommune, Inc. | D | 91% | View Analysis → |
| APUS | Apimeds Pharmaceuticals US, Inc. | C | 90% | View Analysis → |
| JUNS | JUPITER NEUROSCIENCES, INC. | D | 90% | View Analysis → |
| COSM | Cosmos Health Inc. | D | 90% | View Analysis → |
| CNTB | Connect Biopharma Holdings Ltd | C | 90% | View Analysis → |
| APVO | Aptevo Therapeutics Inc. | D | 90% | View Analysis → |
| AKTX | Akari Therapeutics Plc | D | 90% | View Analysis → |
| ELAB | PMGC Holdings Inc. | D | 90% | View Analysis → |
| GOVX | GeoVax Labs, Inc. | D | 90% | View Analysis → |
| QURE | uniQure N.V. | D | 90% | View Analysis → |
| VGLS | VG Life Sciences Inc. | D | 90% | View Analysis → |
| ONCO | Onconetix, Inc. | D | 90% | View Analysis → |
| HURA | TuHURA Biosciences, Inc./NV | D | 90% | View Analysis → |
| RGBPP | Regen BioPharma Inc | D | 90% | View Analysis → |
| BOLT | Bolt Biotherapeutics, Inc. | D | 89% | View Analysis → |
| OCEA | Ocean Biomedical, Inc. | D | 89% | View Analysis → |
| PYXS | Pyxis Oncology, Inc. | D | 88% | View Analysis → |
| OSTX | OS Therapies Inc | D | 88% | View Analysis → |
| MTNB | Matinas BioPharma Holdings, Inc. | D | 88% | View Analysis → |
| LNAI | Lunai Bioworks Inc. | D | 88% | View Analysis → |
| HCWB | HCW Biologics Inc. | D | 88% | View Analysis → |
| GOSS | Gossamer Bio, Inc. | D | 88% | View Analysis → |
| COCP | Cocrystal Pharma, Inc. | D | 88% | View Analysis → |
| WGRX | Wellgistics Health, Inc. | D | 88% | View Analysis → |
| SIGA | SIGA TECHNOLOGIES INC | C | 88% | View Analysis → |
| DWTX | Dogwood Therapeutics, Inc. | D | 88% | View Analysis → |
| KALA | KALA BIO, Inc. | D | 88% | View Analysis → |
| ENVB | Enveric Biosciences, Inc. | D | 88% | View Analysis → |
| TOVX | Theriva Biologics, Inc. | D | 88% | View Analysis → |
| CALC | CalciMedica, Inc. | D | 88% | View Analysis → |
| AEON | AEON Biopharma, Inc. | D | 88% | View Analysis → |
| CYPH | CYPHERPUNK TECHNOLOGIES INC. | C | 88% | View Analysis → |
| ZSTK | ZeroStack Corp. | D | 88% | View Analysis → |
| TXMD | TherapeuticsMD, Inc. | D | 88% | View Analysis → |
| RZLT | Rezolute, Inc. | D | 88% | View Analysis → |
| ASRT | Assertio Holdings, Inc. | D | 88% | View Analysis → |
| CYCN | Cyclerion Therapeutics, Inc. | D | 88% | View Analysis → |
| SNGX | SOLIGENIX, INC. | D | 88% | View Analysis → |
| ATNM | Actinium Pharmaceuticals, Inc. | D | 88% | View Analysis → |
| AMLX | Amylyx Pharmaceuticals, Inc. | C | 88% | View Analysis → |
| PRGO | PERRIGO Co plc | D | 88% | View Analysis → |
| MCRB | Seres Therapeutics, Inc. | D | 88% | View Analysis → |
| EOLS | Evolus, Inc. | C | 88% | View Analysis → |
| BHC | Bausch Health Companies Inc. | C | 88% | View Analysis → |
| VTGN | Vistagen Therapeutics, Inc. | D | 88% | View Analysis → |
| RVRC | Revium Rx. | D | 88% | View Analysis → |
| PTIXW | Protagenic Therapeutics, Inc.new | D | 88% | View Analysis → |
| NRXPW | NRX Pharmaceuticals, Inc. | D | 88% | View Analysis → |
| IVEVF | Inventiva S.A. | C | 88% | View Analysis → |
| RNTX | Rein Therapeutics, Inc. | D | 87% | View Analysis → |
| OMER | OMEROS CORP | D | 87% | View Analysis → |
| NKTR | NEKTAR THERAPEUTICS | D | 87% | View Analysis → |
| SCNX | Scienture Holdings, Inc. | D | 87% | View Analysis → |
| UNCY | Unicycive Therapeutics, Inc. | D | 87% | View Analysis → |
| DARE | Dare Bioscience, Inc. | D | 87% | View Analysis → |
| RARE | Ultragenyx Pharmaceutical Inc. | C | 87% | View Analysis → |
| CYTK | CYTOKINETICS INC | C | 87% | View Analysis → |
| ISCO | International Stem Cell CORP | C | 87% | View Analysis → |
| ALXO | ALX ONCOLOGY HOLDINGS INC | C | 86% | View Analysis → |
| CTXR | Citius Pharmaceuticals, Inc. | D | 86% | View Analysis → |
| FBLG | FibroBiologics, Inc. | D | 86% | View Analysis → |
| DCOY | Decoy Therapeutics Inc. | C | 86% | View Analysis → |
| KPTI | Karyopharm Therapeutics Inc. | D | 86% | View Analysis → |
| MGNX | MACROGENICS INC | C | 86% | View Analysis → |
| AQST | Aquestive Therapeutics, Inc. | C | 86% | View Analysis → |
| DMAC | DiaMedica Therapeutics Inc. | D | 86% | View Analysis → |
| COGT | Cogent Biosciences, Inc. | C | 86% | View Analysis → |
| LLY | ELI LILLY & Co | A | 86% | View Analysis → |
| HSTC | HST Global, Inc. | D | 86% | View Analysis → |
| RMHI | Retrieve Medical Holdings, Inc. | D | 86% | View Analysis → |
| WHWK | Whitehawk Therapeutics, Inc. | D | 85% | View Analysis → |
| SYRE | Spyre Therapeutics, Inc. | D | 85% | View Analysis → |
| SER | Serina Therapeutics, Inc. | D | 85% | View Analysis → |
| SNSE | Sensei Biotherapeutics, Inc. | C | 85% | View Analysis → |
| PGEN | PRECIGEN, INC. | D | 85% | View Analysis → |
| MTVA | MetaVia Inc. | C | 85% | View Analysis → |
| TVRD | Tvardi Therapeutics, Inc. | D | 85% | View Analysis → |
| SLS | SELLAS Life Sciences Group, Inc. | C | 85% | View Analysis → |
| SPRB | SPRUCE BIOSCIENCES, INC. | D | 85% | View Analysis → |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | C | 85% | View Analysis → |
| STTK | Shattuck Labs, Inc. | C | 85% | View Analysis → |
| XNCR | Xencor Inc | D | 85% | View Analysis → |
| GNLX | GENELUX Corp | D | 85% | View Analysis → |
| BBIO | BridgeBio Pharma, Inc. | C | 85% | View Analysis → |
| PTGX | Protagonist Therapeutics, Inc | C | 85% | View Analysis → |
| ZOMDF | Zomedica Corp. | D | 85% | View Analysis → |
| TOIIW | Oncology Institute, Inc. | D | 85% | View Analysis → |
| SXTPW | 60 DEGREES PHARMACEUTICALS, INC. | D | 85% | View Analysis → |
| SNNC | Sibannac, Inc. | D | 85% | View Analysis → |
| RCKTW | ROCKET PHARMACEUTICALS, INC. | D | 85% | View Analysis → |
| OWPC | One World Products, Inc. | D | 85% | View Analysis → |
| LIPO | LIPELLA PHARMACEUTICALS INC. | D | 85% | View Analysis → |
| MDNAF | Medicenna Therapeutics Corp. | C | 85% | View Analysis → |
| ENLV | Enlivex Ltd. | C | 85% | View Analysis → |
| GRDX | GridAI Technologies Corp. | C | 84% | View Analysis → |
| NNVC | NANOVIRICIDES, INC. | C | 84% | View Analysis → |
| HWH | HWH International Inc. | D | 84% | View Analysis → |
| LTRN | Lantern Pharma Inc. | C | 84% | View Analysis → |
| ALLR | Allarity Therapeutics, Inc. | C | 84% | View Analysis → |
| MIST | Milestone Pharmaceuticals Inc. | C | 84% | View Analysis → |
| GANX | Gain Therapeutics, Inc. | C | 84% | View Analysis → |
| ELDN | Eledon Pharmaceuticals, Inc. | C | 84% | View Analysis → |
| ADIL | ADIAL PHARMACEUTICALS, INC. | C | 84% | View Analysis → |
| INM | InMed Pharmaceuticals Inc. | C | 84% | View Analysis → |
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | A | 84% | View Analysis → |
| DRUG | BRIGHT MINDS BIOSCIENCES INC. | C | 84% | View Analysis → |
| GTBP | GT Biopharma, Inc. | D | 83% | View Analysis → |
| LSTA | LISATA THERAPEUTICS, INC. | D | 83% | View Analysis → |
| ONCY | ONCOLYTICS BIOTECH INC | D | 83% | View Analysis → |
| FHTX | Foghorn Therapeutics Inc. | C | 83% | View Analysis → |
| CAPR | CAPRICOR THERAPEUTICS, INC. | C | 83% | View Analysis → |
| NXTS | Nexentis Technologies Inc. | C | 82% | View Analysis → |
| HYPD | HYPERION DEFI, INC. | D | 82% | View Analysis → |
| CVKD | Cadrenal Therapeutics, Inc. | D | 82% | View Analysis → |
| ANVS | Annovis Bio, Inc. | C | 82% | View Analysis → |
| MBIO | MUSTANG BIO, INC. | C | 82% | View Analysis → |
| LGVN | Longeveron Inc. | D | 82% | View Analysis → |
| CRMD | CorMedix Inc. | A | 82% | View Analysis → |
| NERV | Minerva Neurosciences, Inc. | C | 82% | View Analysis → |
| LITS | Lite Strategy, Inc. | C | 82% | View Analysis → |
| AZTR | Azitra, Inc. | C | 82% | View Analysis → |
| ALT | Altimmune, Inc. | C | 82% | View Analysis → |
| IMNN | Imunon, Inc. | D | 82% | View Analysis → |
| BHVN | Biohaven Ltd. | C | 82% | View Analysis → |
| BMEA | Biomea Fusion, Inc. | D | 82% | View Analysis → |
| VTRS | Viatris Inc | C | 82% | View Analysis → |
| AIRS | Airsculpt Technologies, Inc. | C | 82% | View Analysis → |
| VNDA | Vanda Pharmaceuticals Inc. | D | 82% | View Analysis → |
| ALKS | Alkermes plc. | C | 82% | View Analysis → |
| INDV | Indivior Pharmaceuticals, Inc. | C | 82% | View Analysis → |
| ARDX | ARDELYX, INC. | C | 82% | View Analysis → |
| UTHR | UNITED THERAPEUTICS Corp | A+ | 82% | View Analysis → |
| TDOC | Teladoc Health, Inc. | C | 82% | View Analysis → |
| WVE | Wave Life Sciences Ltd. | D | 82% | View Analysis → |
| EPRX | EUPRAXIA PHARMACEUTICALS INC. | C | 82% | View Analysis → |
| IRD | Opus Genetics, Inc. | C | 81% | View Analysis → |
| FBRX | Forte Biosciences, Inc. | C | 81% | View Analysis → |
| ROIV | Roivant Sciences Ltd. | C | 81% | View Analysis → |
| DERM | Journey Medical Corp | C | 81% | View Analysis → |
| OGEN | ORAGENICS INC | D | 81% | View Analysis → |
| CTMX | CytomX Therapeutics, Inc. | C | 81% | View Analysis → |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | A | 81% | View Analysis → |
| GRI | GRI Bio, Inc. | C | 80% | View Analysis → |
| LPCN | Lipocine Inc. | C | 80% | View Analysis → |
| CRVS | Corvus Pharmaceuticals, Inc. | C | 80% | View Analysis → |
| AYTU | AYTU BIOPHARMA, INC | C | 80% | View Analysis → |
| APRE | Aprea Therapeutics, Inc. | C | 80% | View Analysis → |
| LYEL | Lyell Immunopharma, Inc. | C | 80% | View Analysis → |
| AVTX | Avalo Therapeutics, Inc. | D | 80% | View Analysis → |
| CATX | Perspective Therapeutics, Inc. | C | 80% | View Analysis → |
| OGN | Organon & Co. | C | 80% | View Analysis → |
| ELAN | Elanco Animal Health Inc | C | 80% | View Analysis → |
| AMRX | Amneal Pharmaceuticals, Inc. | C | 80% | View Analysis → |
| OKUR | OnKure Therapeutics, Inc. | C | 80% | View Analysis → |
| ADCT | ADC Therapeutics SA | C | 80% | View Analysis → |
| REGN | REGENERON PHARMACEUTICALS, INC. | A | 80% | View Analysis → |
| FULC | Fulcrum Therapeutics, Inc. | C | 80% | View Analysis → |
| TTRX | Turn Therapeutics Inc. | D | 80% | View Analysis → |
| IGC | IGC Pharma, Inc. | C | 80% | View Analysis → |
| MPLT | MapLight Therapeutics, Inc. | C | 80% | View Analysis → |
| FBIOP | Fortress Biotech, Inc. | C | 80% | View Analysis → |
| IMUX | IMMUNIC, INC. | C | 79% | View Analysis → |
| CLRB | Cellectar Biosciences, Inc. | C | 79% | View Analysis → |
| GNPX | Genprex, Inc. | C | 79% | View Analysis → |
| KYNB | KYNTRA BIO, INC. | C | 79% | View Analysis → |
| BOLD | Boundless Bio, Inc. | C | 79% | View Analysis → |
| ZBIO | Zenas BioPharma, Inc. | C | 78% | View Analysis → |
| SCYX | SCYNEXIS INC | C | 78% | View Analysis → |
| RVPH | REVIVA PHARMACEUTICALS HOLDINGS, INC. | C | 78% | View Analysis → |
| ACTU | ACTUATE THERAPEUTICS, INC. | C | 78% | View Analysis → |
| TRDA | Entrada Therapeutics, Inc. | C | 78% | View Analysis → |
| RNAC | Cartesian Therapeutics, Inc. | C | 78% | View Analysis → |
| HOWL | Werewolf Therapeutics, Inc. | D | 78% | View Analysis → |
| EWTX | Edgewise Therapeutics, Inc. | C | 78% | View Analysis → |
| ACRS | Aclaris Therapeutics, Inc. | C | 78% | View Analysis → |
| RNAZ | Transcode Therapeutics, Inc. | D | 78% | View Analysis → |
| TELO | Telomir Pharmaceuticals, Inc. | C | 78% | View Analysis → |
| PDSB | PDS Biotechnology Corp | D | 78% | View Analysis → |
| CNTA | Centessa Pharmaceuticals plc | C | 78% | View Analysis → |
| LIXT | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | C | 78% | View Analysis → |
| ERAS | Erasca, Inc. | C | 78% | View Analysis → |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | C | 78% | View Analysis → |
| BCAX | Bicara Therapeutics Inc. | B | 78% | View Analysis → |
| AUPH | Aurinia Pharmaceuticals Inc. | A | 78% | View Analysis → |
| ANNX | Annexon, Inc. | C | 78% | View Analysis → |
| PMVP | PMV Pharmaceuticals, Inc. | C | 78% | View Analysis → |
| CPRX | CATALYST PHARMACEUTICALS, INC. | A | 78% | View Analysis → |
| ZTS | Zoetis Inc. | A | 78% | View Analysis → |
| SMMT | Summit Therapeutics Inc. | C | 78% | View Analysis → |
| QNRX | Quoin Pharmaceuticals, Ltd. | D | 78% | View Analysis → |
| ABBV | AbbVie Inc. | C | 78% | View Analysis → |
| URGN | UroGen Pharma Ltd. | C | 78% | View Analysis → |
| LFCR | LIFECORE BIOMEDICAL, INC. DE | C | 78% | View Analysis → |
| IRWD | IRONWOOD PHARMACEUTICALS INC | C | 78% | View Analysis → |
| GRDN | Guardian Pharmacy Services, Inc. | B | 78% | View Analysis → |
| GERN | GERON CORP | C | 78% | View Analysis → |
| BRNS | Barinthus Biotherapeutics plc. | C | 78% | View Analysis → |
| AMPH | Amphastar Pharmaceuticals, Inc. | C | 78% | View Analysis → |
| SDGR | Schrodinger, Inc. | C | 78% | View Analysis → |
| PCRX | Pacira BioSciences, Inc. | C | 78% | View Analysis → |
| MRK | Merck & Co., Inc. | B | 78% | View Analysis → |
| EBS | Emergent BioSolutions Inc. | C | 78% | View Analysis → |
| IONS | IONIS PHARMACEUTICALS INC | C | 78% | View Analysis → |
| AGIO | AGIOS PHARMACEUTICALS, INC. | C | 78% | View Analysis → |
| TERN | Terns Pharmaceuticals, Inc. | C | 78% | View Analysis → |
| SBFMW | Sunshine Biopharma Inc. | C | 78% | View Analysis → |
| PTPI | Petros Pharmaceuticals, Inc. | D | 78% | View Analysis → |
| PLYX | Polaryx Therapeutics, Inc. | C | 78% | View Analysis → |
| NAMSW | NewAmsterdam Pharma Co N.V. | C | 78% | View Analysis → |
| KPHMW | KIORA PHARMACEUTICALS INC | C | 78% | View Analysis → |
| IXHL | Incannex Healthcare Inc. | C | 77% | View Analysis → |
| EDSA | Edesa Biotech, Inc. | C | 77% | View Analysis → |
| ARVN | ARVINAS, INC. | C | 77% | View Analysis → |
| RMTI | ROCKWELL MEDICAL, INC. | C | 77% | View Analysis → |
| CRNX | Crinetics Pharmaceuticals, Inc. | C | 77% | View Analysis → |
| CNTX | Context Therapeutics Inc. | C | 77% | View Analysis → |
| CYRX | Cryoport, Inc. | C | 77% | View Analysis → |
| NEUP | Neuphoria Therapeutics Inc. | C | 76% | View Analysis → |
| NKTX | Nkarta, Inc. | C | 76% | View Analysis → |
| CMPS | COMPASS Pathways plc | C | 76% | View Analysis → |
| AARD | Aardvark Therapeutics, Inc. | C | 76% | View Analysis → |
| COYA | Coya Therapeutics, Inc. | C | 76% | View Analysis → |
| ATOS | ATOSSA THERAPEUTICS, INC. | C | 76% | View Analysis → |
| ACET | Adicet Bio, Inc. | C | 76% | View Analysis → |
| HROW | HARROW, INC. | C | 76% | View Analysis → |
| AVBP | ArriVent BioPharma, Inc. | C | 76% | View Analysis → |
| KURA | Kura Oncology, Inc. | C | 76% | View Analysis → |
| ARCT | Arcturus Therapeutics Holdings Inc. | C | 76% | View Analysis → |
| MIRM | Mirum Pharmaceuticals, Inc. | B | 76% | View Analysis → |
| IRON | Disc Medicine, Inc. | C | 76% | View Analysis → |
| ACAD | ACADIA PHARMACEUTICALS INC | C | 76% | View Analysis → |
| HRMY | Harmony Biosciences Holdings, Inc. | A | 76% | View Analysis → |
| BMRN | BIOMARIN PHARMACEUTICAL INC | A | 76% | View Analysis → |
| AXSM | Axsome Therapeutics, Inc. | C | 76% | View Analysis → |
| PULM | Pulmatrix, Inc. | D | 75% | View Analysis → |
| HIND | Vyome Holdings, Inc | C | 75% | View Analysis → |
| VYNE | VYNE Therapeutics Inc. | C | 75% | View Analysis → |
| JANX | Janux Therapeutics, Inc. | C | 75% | View Analysis → |
| ZNTL | Zentalis Pharmaceuticals, Inc. | C | 75% | View Analysis → |
| XBIT | XBiotech Inc. | D | 75% | View Analysis → |
| VERU | VERU INC. | C | 75% | View Analysis → |
| ANRO | Alto Neuroscience, Inc. | C | 75% | View Analysis → |
| ANTX | AN2 Therapeutics, Inc. | C | 75% | View Analysis → |
| ENTA | ENANTA PHARMACEUTICALS INC | C | 75% | View Analysis → |
| PMN | ProMIS Neurosciences Inc. | C | 75% | View Analysis → |
| PRLD | Prelude Therapeutics Inc | D | 75% | View Analysis → |
| ZLAB | Zai Lab Ltd | C | 75% | View Analysis → |
| PBYI | PUMA BIOTECHNOLOGY, INC. | C | 75% | View Analysis → |
| NUS | NU SKIN ENTERPRISES, INC. | C | 75% | View Analysis → |
| COLL | COLLEGIUM PHARMACEUTICAL, INC | A | 75% | View Analysis → |
| CVS | CVS HEALTH Corp | C | 75% | View Analysis → |
| PRAX | Praxis Precision Medicines, Inc. | C | 75% | View Analysis → |
| SRPT | Sarepta Therapeutics, Inc. | C | 75% | View Analysis → |
| CORT | CORCEPT THERAPEUTICS INC | C | 75% | View Analysis → |
| AMRN | AMARIN CORP PLCUK | C | 75% | View Analysis → |
| PCYN | PROCYON CORP | C | 75% | View Analysis → |
| KAPA | Kairos Pharma, LTD. | C | 74% | View Analysis → |
| ELVN | Enliven Therapeutics, Inc. | C | 74% | View Analysis → |
| ABUS | Arbutus Biopharma Corp | C | 74% | View Analysis → |
| CNTN | Canton Strategic Holdings, Inc. | C | 74% | View Analysis → |
| NGNE | Neurogene Inc. | C | 74% | View Analysis → |
| ANIP | ANI PHARMACEUTICALS INC | A | 74% | View Analysis → |
| MCK | MCKESSON CORP | A | 74% | View Analysis → |
| LXRX | LEXICON PHARMACEUTICALS, INC. | C | 74% | View Analysis → |
| BIOA | BioAge Labs, Inc. | B | 74% | View Analysis → |
| MNKD | MANNKIND CORP | C | 74% | View Analysis → |
| INVA | Innoviva, Inc. | A | 74% | View Analysis → |
| HLF | HERBALIFE LTD. | C | 74% | View Analysis → |
| COR | Cencora, Inc. | C | 74% | View Analysis → |
| ARQT | Arcutis Biotherapeutics, Inc. | C | 74% | View Analysis → |
| OPK | OPKO HEALTH, INC. | C | 74% | View Analysis → |
| ABT | ABBOTT LABORATORIES | B | 74% | View Analysis → |
| LGNZZ | LIGAND PHARMACEUTICALS INC | A | 74% | View Analysis → |
| NUVL | Nuvalent, Inc. | C | 73% | View Analysis → |
| MRKR | Marker Therapeutics, Inc. | C | 72% | View Analysis → |
| TBPH | Theravance Biopharma, Inc. | A | 72% | View Analysis → |
| SGMT | Sagimet Biosciences Inc. | C | 72% | View Analysis → |
| RAPP | Rapport Therapeutics, Inc. | C | 72% | View Analysis → |
| DYN | Dyne Therapeutics, Inc. | C | 72% | View Analysis → |
| RANI | Rani Therapeutics Holdings, Inc. | C | 72% | View Analysis → |
| TLPH | TALPHERA, INC. | C | 72% | View Analysis → |
| ORKA | Oruka Therapeutics, Inc. | C | 72% | View Analysis → |
| BNTC | Benitec Biopharma Inc. | C | 72% | View Analysis → |
| ABEO | ABEONA THERAPEUTICS INC. | C | 72% | View Analysis → |
| XBIO | Xenetic Biosciences, Inc. | C | 72% | View Analysis → |
| SPRO | Spero Therapeutics, Inc. | C | 72% | View Analysis → |
| TNXP | Tonix Pharmaceuticals Holding Corp. | C | 72% | View Analysis → |
| HIMS | Hims & Hers Health, Inc. | A | 72% | View Analysis → |
| AVIR | Atea Pharmaceuticals, Inc. | C | 72% | View Analysis → |
| ABCL | AbCellera Biologics Inc. | C | 72% | View Analysis → |
| NXTC | NextCure, Inc. | C | 72% | View Analysis → |
| MRVI | MARAVAI LIFESCIENCES HOLDINGS, INC. | C | 72% | View Analysis → |
| ESPR | Esperion Therapeutics, Inc. | C | 72% | View Analysis → |
| RPRX | Royalty Pharma plc | B | 72% | View Analysis → |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | C | 72% | View Analysis → |
| DSGN | Design Therapeutics, Inc. | C | 72% | View Analysis → |
| NATR | NATURES SUNSHINE PRODUCTS INC | B | 72% | View Analysis → |
| JBIO | Jade Biosciences, Inc. | C | 72% | View Analysis → |
| VRDN | Viridian Therapeutics, Inc.\DE | D | 72% | View Analysis → |
| RYTM | RHYTHM PHARMACEUTICALS, INC. | C | 72% | View Analysis → |
| VREOF | Vireo Growth Inc. | C | 72% | View Analysis → |
| LIFD | LFTD PARTNERS INC. | C | 72% | View Analysis → |
| LIANY | LianBio | C | 72% | View Analysis → |
| GRTX | Galera Therapeutics, Inc. | C | 72% | View Analysis → |
| REVBW | REVELATION BIOSCIENCES, INC. | C | 72% | View Analysis → |
| NRIX | Nurix Therapeutics, Inc. | C | 72% | View Analysis → |
| ALDX | Aldeyra Therapeutics, Inc. | C | 71% | View Analysis → |
| IMNM | Immunome Inc. | C | 71% | View Analysis → |
| IBIO | iBio, Inc. | C | 71% | View Analysis → |
| OCUL | OCULAR THERAPEUTIX, INC | C | 71% | View Analysis → |
| RNXT | RenovoRx, Inc. | C | 70% | View Analysis → |
| RLYB | Rallybio Corp | C | 70% | View Analysis → |
| PLRX | PLIANT THERAPEUTICS, INC. | B | 70% | View Analysis → |
| CTNM | Contineum Therapeutics, Inc. | C | 70% | View Analysis → |
| CLYM | Climb Bio, Inc. | C | 70% | View Analysis → |
| CBIO | CRESCENT BIOPHARMA, INC. | C | 70% | View Analysis → |
| ACRV | Acrivon Therapeutics, Inc. | C | 70% | View Analysis → |
| MNOV | MEDICINOVA INC | C | 70% | View Analysis → |
| ETON | Eton Pharmaceuticals, Inc. | A | 70% | View Analysis → |
| RLMD | RELMADA THERAPEUTICS, INC. | C | 70% | View Analysis → |
| MBX | MBX Biosciences, Inc. | B | 70% | View Analysis → |
| HRTX | HERON THERAPEUTICS, INC. /DE/ | C | 70% | View Analysis → |
| STOK | Stoke Therapeutics, Inc. | C | 70% | View Analysis → |
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | A | 70% | View Analysis → |
| MLYS | Mineralys Therapeutics, Inc. | C | 70% | View Analysis → |
| TGTX | TG THERAPEUTICS, INC. | C | 70% | View Analysis → |
| SBCWW | SBC Medical Group Holdings Inc | B | 70% | View Analysis → |
| LEXX | Lexaria Bioscience Corp. | C | 70% | View Analysis → |
| LBRX | LB PHARMACEUTICALS INC | C | 70% | View Analysis → |
| RFL | Rafael Holdings, Inc. | C | 70% | View Analysis → |
| CAMP | Camp4 Therapeutics Corp | C | 69% | View Analysis → |
| GRCE | Grace Therapeutics, Inc. | B | 69% | View Analysis → |
| XLO | Xilio Therapeutics, Inc. | B | 68% | View Analysis → |
| PEPG | PepGen Inc. | C | 68% | View Analysis → |
| ASMB | ASSEMBLY BIOSCIENCES, INC. | C | 68% | View Analysis → |
| PBH | Prestige Consumer Healthcare Inc. | B | 68% | View Analysis → |
| ATAI | Atai Beckley N.V. | C | 68% | View Analysis → |
| LRMR | Larimar Therapeutics, Inc. | C | 68% | View Analysis → |
| OVID | Ovid Therapeutics Inc. | C | 68% | View Analysis → |
| MREO | Mereo BioPharma Group plc | C | 68% | View Analysis → |
| TNGX | Tango Therapeutics, Inc. | B | 68% | View Analysis → |
| SION | Sionna Therapeutics, Inc. | B | 68% | View Analysis → |
| MLTX | MoonLake Immunotherapeutics | C | 68% | View Analysis → |
| LQDA | Liquidia Corp | A | 68% | View Analysis → |
| ANAB | ANAPTYSBIO, INC | B | 68% | View Analysis → |
| ZYME | Zymeworks Inc. | C | 68% | View Analysis → |
| PRTA | PROTHENA CORP PUBLIC LTD CO | C | 68% | View Analysis → |
| PAHC | PHIBRO ANIMAL HEALTH CORP | B | 68% | View Analysis → |
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | B | 68% | View Analysis → |
| JAZZ | Jazz Pharmaceuticals plc | C | 68% | View Analysis → |
| TVTX | Travere Therapeutics, Inc. | B | 68% | View Analysis → |
| NUVB | Nuvation Bio Inc. | B | 68% | View Analysis → |
| XOMAP | XOMA Royalty Corp | B | 68% | View Analysis → |
| INBP | INTEGRATED BIOPHARMA INC | C | 68% | View Analysis → |
| FOLD | AMICUS THERAPEUTICS, INC. | A | 68% | View Analysis → |
| IMMX | Immix Biopharma, Inc. | C | 67% | View Analysis → |
| CUE | Cue Biopharma, Inc. | C | 67% | View Analysis → |
| BCYC | BICYCLE THERAPEUTICS PLC | B | 67% | View Analysis → |
| APLS | Apellis Pharmaceuticals, Inc. | A | 67% | View Analysis → |
| NVCT | Nuvectis Pharma, Inc. | C | 67% | View Analysis → |
| KTTAW | Pasithea Therapeutics Corp. | C | 67% | View Analysis → |
| AKBA | Akebia Therapeutics, Inc. | C | 66% | View Analysis → |
| MIRA | MIRA PHARMACEUTICALS, INC. | C | 66% | View Analysis → |
| ALMS | ALUMIS INC. | C | 66% | View Analysis → |
| MNPR | Monopar Therapeutics | C | 66% | View Analysis → |
| OLMA | Olema Pharmaceuticals, Inc. | C | 66% | View Analysis → |
| RIGL | RIGEL PHARMACEUTICALS INC | B | 66% | View Analysis → |
| ORIC | Oric Pharmaceuticals, Inc. | C | 66% | View Analysis → |
| KNSA | Kiniksa Pharmaceuticals International, plc | A | 66% | View Analysis → |
| SEPN | Septerna, Inc. | C | 65% | View Analysis → |
| PHIO | Phio Pharmaceuticals Corp. | B | 65% | View Analysis → |
| IMRX | Immuneering Corp | C | 65% | View Analysis → |
| UPB | Upstream Bio, Inc. | B | 65% | View Analysis → |
| XERS | Xeris Biopharma Holdings, Inc. | B | 65% | View Analysis → |
| PTCT | PTC THERAPEUTICS, INC. | B | 65% | View Analysis → |
| RCUS | Arcus Biosciences, Inc. | C | 65% | View Analysis → |
| PHAT | Phathom Pharmaceuticals, Inc. | C | 65% | View Analysis → |
| EQ | Equillium, Inc. | C | 64% | View Analysis → |
| GYRE | GYRE THERAPEUTICS, INC. | B | 64% | View Analysis → |
| INSM | INSMED Inc | C | 64% | View Analysis → |
| LFVN | Lifevantage Corp | B | 64% | View Analysis → |
| ACXP | Acurx Pharmaceuticals, Inc. | C | 63% | View Analysis → |
| LFMDP | LifeMD, Inc. | A | 63% | View Analysis → |
| VTVT | vTv Therapeutics Inc. | B | 62% | View Analysis → |
| TYRA | Tyra Biosciences, Inc. | B | 62% | View Analysis → |
| GPCR | Structure Therapeutics Inc. | B | 62% | View Analysis → |
| HOTH | Hoth Therapeutics, Inc. | C | 62% | View Analysis → |
| ORGO | Organogenesis Holdings Inc. | C | 62% | View Analysis → |
| ZVRA | ZEVRA THERAPEUTICS, INC. | B | 62% | View Analysis → |
| SLNO | SOLENO THERAPEUTICS INC | A | 62% | View Analysis → |
| CPIX | CUMBERLAND PHARMACEUTICALS INC | C | 60% | View Analysis → |
| PFE | PFIZER INC | B | 60% | View Analysis → |
| KRRO | Korro Bio, Inc. | C | 59% | View Analysis → |
| VRCA | Verrica Pharmaceuticals Inc. | B | 58% | View Analysis → |
| MSLE | Satellos Bioscience Inc. | C | 58% | View Analysis → |
| GLSI | Greenwich LifeSciences, Inc. | C | 57% | View Analysis → |
| KROS | Keros Therapeutics, Inc. | A | 57% | View Analysis → |
| ORMP | ORAMED PHARMACEUTICALS INC. | C | 56% | View Analysis → |
| HOOK | HOOKIPA Pharma Inc. | C | 56% | View Analysis → |
| KZR | Kezar Life Sciences, Inc. | C | 55% | View Analysis → |
| PVLA | PALVELLA THERAPEUTICS, INC. | B | 55% | View Analysis → |
| IDYA | IDEAYA Biosciences, Inc. | B | 54% | View Analysis → |
| KALV | KalVista Pharmaceuticals, Inc. | B | 54% | View Analysis → |
| ETST | Earth Science Tech, Inc. | B | 52% | View Analysis → |
| TRVI | Trevi Therapeutics, Inc. | C | 50% | View Analysis → |
| SNDX | Syndax Pharmaceuticals Inc | B | 48% | View Analysis → |
| GENB | Generate Biomedicines, Inc. | C | 46% | View Analysis → |
| VKTX | Viking Therapeutics, Inc. | C | 45% | View Analysis → |
| TEVJF | TEVA PHARMACEUTICAL INDUSTRIES LTD | B | 45% | View Analysis → |
| GDTC | CytoMed Therapeutics Ltd | C | 44% | View Analysis → |
| EVOTF | Evotec SE | C | 44% | View Analysis → |
| XENE | Xenon Pharmaceuticals Inc. | B | 42% | View Analysis → |
| VSTM | Verastem, Inc. | B | 42% | View Analysis → |
| GHRS | GH Research PLC | B | 40% | View Analysis → |
| QTTB | Q32 Bio Inc. | C | 35% | View Analysis → |
| TENX | TENAX THERAPEUTICS, INC. | B | 35% | View Analysis → |
| VERA | Vera Therapeutics, Inc. | D | 35% | View Analysis → |
| SYBX | SYNLOGIC, INC. | D | 35% | View Analysis → |
| RLFTF | Relief Therapeutics Holding SA | C | 32% | View Analysis → |
| RDGT | Ridgetech Inc. | C | 22% | View Analysis → |
| RNA | Atrium Therapeutics, Inc. | C | 21% | View Analysis → |
| NRSNW | NeuroSense Therapeutics Ltd. | B | 20% | View Analysis → |
| NSRX | Nasus Pharma Ltd | B | 18% | View Analysis → |
| NONOF | NOVO NORDISK A S | B | 18% | View Analysis → |
| RDHL | RedHill Biopharma Ltd. | B | 16% | View Analysis → |
| RDY | DR REDDYS LABORATORIES LTD | B | 15% | View Analysis → |
| RDPTF | Radiopharm Theranostics Ltd | B | 14% | View Analysis → |
Frequently Asked Questions: Pharmaceutical Stocks
What are the best pharmaceutical stocks to buy in 2026?
Based on our dual AI fundamental analysis (Claude and ChatGPT), 27 pharmaceutical stocks have A+ or A grades in 2026. These are ranked by confidence score based on SEC 10-K and 10-Q filing analysis.
Which pharmaceutical stocks have A+ grades?
Currently, 1 pharmaceutical stocks have an A+ grade from our AI analysis. A+ indicates both Claude and ChatGPT agree on exceptional fundamentals with high confidence scores above 80%.
How does AI analyze pharmaceutical stocks?
Our dual AI system analyzes SEC EDGAR filings including revenue growth, profit margins, ROE, ROA, debt levels, and cash flow. Both Claude (Anthropic) and ChatGPT (OpenAI) independently evaluate each stock, then we combine their ratings for higher accuracy.
What is the AI confidence score?
AI confidence scores range from 0-100% and indicate how strongly the AI models agree on their rating. Higher confidence means clearer signals from SEC filing data. Pharmaceutical stocks with 80%+ confidence have the most reliable ratings.
Should I invest in pharmaceutical stocks in 2026?
Our AI analysis shows 27 Buy ratings vs 412 Sell ratings in the pharmaceutical sector. Individual stock fundamentals vary significantly - review each stock's detailed analysis. This is not investment advice.
How often are pharmaceutical stock ratings updated?
AI ratings are updated whenever companies file new SEC reports (10-K annually, 10-Q quarterly). Most pharmaceutical stocks are re-analyzed within 24-48 hours of new filings being published on SEC EDGAR.
What data sources are used for pharmaceutical stock analysis?
All analysis is based on official SEC EDGAR filings including Form 10-K (annual reports), Form 10-Q (quarterly reports), and other regulatory disclosures. We do not use price data or market sentiment - only fundamental financial data.
Compare Top Pharmaceutical Stocks
Part of: 💊 Healthcare Sector